• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    11/14/24 4:31:38 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email
    SC 13G/A 1 p24-3185sc13ga.htm SAGIMET BIOSCIENCES INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1 )*
     

    Sagimet Biosciences Inc.

    (Name of Issuer)
     

    Series A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    786700104

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ý Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 78670010413G/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    724,800

    6

    SHARED VOTING POWER

    -0-

    7

    SOLE DISPOSITIVE POWER

    724,800

    8

    SHARED DISPOSITIVE POWER

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    724,800

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.4%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

    CUSIP No. 78670010413G/APage 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Sagimet Biosciences Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
      The Company's principal executive office is located at 155 Bovet Road, Suite 303, San Mateo, California 94402.
    Item 2(a). NAME OF PERSON FILING
     

    This statement is filed by Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM" or the "Reporting Person"), with respect to the shares of Series A Common Stock (as defined in Item 2(d) below) held by SGMT Holdings Limited ("SGMT"). SGMT is wholly owned by Hillhouse Venture Fund V, L.P. ("Venture Fund V"). HIM acts as the sole management company of Venture Fund V. HIM is hereby deemed to be the sole beneficial owner of, and to solely control the voting and investment power of, the shares of Series A Common Stock held by SGMT.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of the Reporting Person is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.

     

    Item 2(c). CITIZENSHIP
      Cayman Islands

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Series A Common Stock, par value $0.0001 per share (the "Series A Common Stock").

     

    Item 2(e). CUSIP NUMBER
      786700104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

     

    CUSIP No. 78670010413G/APage 4 of 5 Pages

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ___________________________________

     

    Item 4. OWNERSHIP
      The percentage set forth in this Schedule 13G is calculated based upon an aggregate of  30,674,855 shares of Series A Common Stock outstanding as of August 14, 2024, as reported in the Company's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on August 15, 2024.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION
      Not applicable.

     

     

     

    CUSIP No. 78670010413G/APage 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 14, 2024

     

    HILLHOUSE Investment MANAGEMENT, LTD.  
       
       
    /s/ Audrey Woon  
    Name:  Audrey Woon  
    Title:    Chief Compliance Officer  

     

    Get the next $SGMT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    8/11/2025$28.00Outperform
    Wedbush
    8/7/2025$29.00Buy
    H.C. Wainwright
    7/24/2025$28.00Buy
    Canaccord Genuity
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    More analyst ratings

    $SGMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Happel David sold $598,115 worth of Series A Common Stock (65,478 units at $9.13), decreasing direct ownership by 9% to 689,722 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:16:25 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Martins Eduardo Bruno sold $75,607 worth of Series A Common Stock (8,277 units at $9.13), decreasing direct ownership by 7% to 106,936 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:15:22 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel and CCO Rozek Elizabeth sold $98,471 worth of Series A Common Stock (10,780 units at $9.13), decreasing direct ownership by 6% to 183,726 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:14:11 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Sagimet Biosciences with a new price target

    Wedbush initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $28.00

    8/11/25 10:06:29 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Sagimet Biosciences with a new price target

    H.C. Wainwright resumed coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $29.00

    8/7/25 7:42:15 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Sagimet Biosciences with a new price target

    Canaccord Genuity initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $28.00

    7/24/25 7:28:22 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Happel David bought $63,731 worth of Series A Common Stock (12,100 units at $5.27), increasing direct ownership by 2% to 639,200 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    3/28/24 4:08:37 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

    Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S. Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 SAN MATEO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial result

    8/13/25 7:30:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

    SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutical company developing no

    8/5/25 7:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025

    SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 2:00 PM ET. To register, click here. The event will feature key opinion leader (KOL) Neal Bhatia, MD (Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego), who will join company management to review positive efficacy and tolerability results from a Phase 3 clinical trial evaluating denifanstat for the treatment of moderate to severe acne vulgar

    6/9/25 7:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    SEC Filings

    View All

    Sagimet Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    8/14/25 5:02:06 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Sagimet Biosciences Inc.

    424B5 - Sagimet Biosciences Inc. (0001400118) (Filer)

    8/14/25 4:58:22 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    8/13/25 7:36:20 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sagimet Biosciences Inc.

    SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 5:05:18 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 4:31:38 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Financials

    Live finance-specific insights

    View All

    Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202

    8/14/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

    SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi

    6/10/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Leadership Updates

    Live Leadership Updates

    View All

    Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

    SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

    5/6/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

    3/25/24 7:00:00 AM ET
    $IPSC
    $MIRM
    $RPHM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations